Novartis announced that after conducting an interim analysis from the CIRRUS-1 trial of CFZ533 (iscalimab), the company is discontinuing the study in kidney transplant patients.

The U.S. Food and Drug Administration greenlit AstraZeneca’s Farxiga (dapagliflozin) under priority review for the treatment of chronic kidney disease in patients at risk of progression with or without type 2 diabetes.

Alnylam Pharmaceuticals reported positive results for the ILLUMINATE-B Phase III clinical trial evaluating the RNAi therapeutic lumasiran in young children with primary hyperoxaluria type 1 (PH1).